Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, methods of treating a cancer or tumor, methods of reducing tumor load, methods of reducing the size or growth rate of a cancer or a tumor, and methods of extending of the survival of a subject suffering from a cancer or tumor, wherein the subjects are administered compositions comprising apoptotic cells or apoptotic cell supernatants. Compositions and methods of use thereof may increase the efficacy of a CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm. In certain instances compositions may include additional chemotherapeutic or immunomodulatory agents.

The disclosure provided herein relates generally to mesenchymal-like stem cells hES-T-MiSC or T-MSC and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cell and cell lineages T-MSC-DL are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.

A method for sterilising a platelet lysate in the liquid state comprising at least the endogenous growth factors TGF-beta 1, EGF, PDGF-AB, IGF-1, VEGF and bFGF. The method comprising freezing the liquid platelet lysate in order to obtain a frozen platelet lysate, and irradiating the frozen platelet lysate with ionising radiation in order to obtain a sterilised platelet lysate, the irradiation being adapted so as to preserve at least 80% of the concentration of at least one of the endogenous growth factors chosen from the group consisting of TGF-beta 1, EGF, PDGF-AB, IGF-1 and VEGF.

The invention relates to a carrying device for beverage cans which allows the manual carrying of beverage cans grouped together in the form of a pack, which device comprises a body devoid of side walls, having on its surface at least one opening defining a contour with proportions which allow the tight passage therethrough of a beverage can, the contour of said opening having a plurality of tabs that can be folded or bent in relation to the body itself and extending into the same opening, said tabs having a distribution according to at least one sequence, said sequence comprising two contiguous tabs followed by a gap followed by another tab followed by another gap.

Methods and systems for generating a tunable or customizable activated product composition are related. In certain embodiments, one or more of electric pulse parameters, flow rate, or sample container size are varied so as to generate the activated product composition. The activated product composition may be customized or optimized based for a particular patient or procedure.

The present invention relates to a method of preparing magnetic oocytes and/or embryos by means of nanoparticles for assisted reproduction techniques and to the use in assisted reproduction techniques of non-human oocytes and/or embryos prepared with said method. Said method comprises: a step in which magnetic nanoparticles are conjugated with oviduct recombinant protein, OVGP1r; a step in which it is verified that the nanoparticle-OVGP1r conjugation attaches to the ZP of oocytes/embryos after being incubated together; and a step in which the number of oocytes/embryos having nanoparticles attached to them distributed around the ZP without being endocytosed is verified; and it is assessed if the amount of magnetic nanoparticles attached to the ZP of oocytes/embryos is enough to be attracted by a magnetic field.

A cell therapy structure and method, including a matrix of fibers of a proteinaceous material and an electrically conductive material. The aligned fibers are spun from a combination the electrically conductive material, such as carbon nanotubes, and a fibroin material or a collagen material. A method of tissue engineering includes seeding a cell culture on a matrix of electrically conductive protein fibers, applying an electric current to the matrix to stimulate the cell culture, and applying the simulated cell culture to a tissue.

The present invention provides methods of identifying and distinguishing different types of nerve cells in ex vivo cell culture, the method comprising the steps of: a) culturing somato-sensory nerve cells ex vivo, b) loading the nerve cells with a calcium, sodium, or voltage-sensitive indicator or expressing a genetically encoded calcium, sodium, or voltage-sensitive indicator, c) pulsing the nerve cells with an electrical train of bipolar square waves at two different voltages and two different frequencies; wherein the first voltage is 10 V/cm or less (low voltage) and the second voltage is between 12 and 20 V/cm (high voltage); and wherein the first frequency is 5 Hz or less (low frequency) and the second frequency is between 15 and 20 Hz (high frequency), and d) detecting activation of the nerve cell by measuring the changes in the signal intensity of the indicator, wherein low voltage and low frequency activation indicates a first type of cell and activation detected only at high voltage indicates a second type of cell.

The present disclosure provides a system for regulating expression of a target polynucleotide in a cell. The system may comprise a chimeric polypeptide comprising a gene modulating polypeptide fused in-frame with a heterologous nuclear localization domain. The heterologous nuclear localization domain may be operable to translocate the chimeric polypeptide to a cell nucleus upon activation by an active cellular signaling pathway. The cellular signaling pathway may be inducible in response to an extracellular signal. In response to the extracellular signal, the chimeric polypeptide may localize to the cell nucleus and the gene modulating polypeptide may regulate expression of a target polynucleotide in the cell nucleus.

There is provided systems and methods for performing fluidic perfusion, recirculation and interacting organ in standard wells or microfluidic reactors loading cells or organs into an insert or chip. The perfusion system can provide new media to the cell or organs while the circulation system can provide convective mixing of fluids within a well or between one or more organs in an assay. The system can be placed in an incubator or microscope and perform multimodal stimulation and sensing. The system includes electromechanical control, microfluidic lid and inserts or chips for performing automated cell based assay, organ of a chip or human on a chip in a remote-controlled environment.